Eli Lilly (LLY) Invested Capital (2009 - 2026)

Eli Lilly (LLY) has reported Invested Capital for 18 consecutive years, with $72.8 billion the latest figure, recorded in Q1 2026.

• Invested Capital for Q1 2026 came in at $72.8 billion, up 1685.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $72.8 billion (up 1685.02% YoY), and the FY2025 annual result was $69.0 billion, up 160.57% from the prior year.
• Invested Capital was $72.8 billion for Q1 2026 at Eli Lilly, up from $69.0 billion in the prior quarter.
• Over five years, Invested Capital peaked at $72.8 billion in Q1 2026 and troughed at -$4.3 billion in Q1 2024.
• Average Invested Capital over 5 years is $20.2 billion, with a median of $14.9 billion recorded in 2022.
• Year-over-year, Invested Capital sank 4086.0% in 2024 and soared 3489.19% in 2025.
• Over 5 years, Invested Capital stood at $14.9 billion in 2022, then increased by 7.95% to $16.1 billion in 2023, then soared by 64.65% to $26.5 billion in 2024, then soared by 160.57% to $69.0 billion in 2025, then gained by 5.44% to $72.8 billion in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were $72.8 billion in Q1 2026, $69.0 billion in Q4 2025, and $63.8 billion in Q3 2025.